1. The humoral immune response to the inactivated influenza A (H1N1) 2009 monovalent vaccine in patients with Type 2 diabetes mellitus in Korea.
- Author
-
Nam JS, Kim AR, Yoon JC, Byun Y, Kim SA, Kim KR, Cho S, Seong BL, Ahn CW, and Lee JM
- Subjects
- Adolescent, Adult, Aged, Antibodies, Viral immunology, Antibody Formation immunology, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 epidemiology, Enzyme-Linked Immunosorbent Assay, Female, Humans, Immunity, Humoral, Influenza, Human epidemiology, Korea epidemiology, Male, Middle Aged, Risk Factors, Young Adult, Diabetes Mellitus, Type 2 immunology, Influenza A Virus, H1N1 Subtype immunology, Influenza Vaccines immunology, Influenza, Human prevention & control
- Abstract
Aims: We evaluated the antibody response to a single-dose adjuvanted, inactivated, pandemic H1N1 influenza vaccination in patients with diabetes and assessed factors associated with the failure to induce antibody responses., Methods: Eighty-two patients with Type 2 diabetes were vaccinated and antibody responses were determined with haemagglutination inhibition assay and anti-haemagglutinin antibody ELISA., Results: Among 70 antibody-negative patients at baseline, 34 (48.6%) achieved seroconversion; 28 (60.9%) in the young adults group and six (25%) in the elderly group acquired H1N1-specific antibodies. Patients in the older age range or with longer duration of diabetes had a lower seroconversion rate., Conclusions: Our data show low cross-reactive antibody carrying rate and low seroconversion rate in patients with diabetes. Until larger-scale, case-controlled trials become available, older patients and patients with a longer duration of diabetes should be considered for the two-dose vaccination or have antibody titres measured after the first vaccination., (© 2011 The Authors. Diabetic Medicine © 2011 Diabetes UK.)
- Published
- 2011
- Full Text
- View/download PDF